Premier Biomedical Announces Intended $6 Million Investment by Brazilian Joint Venture Partner, Auramedi, to Manufacture, Market and Distribute Premier’s New Technology Products

EL PASO, Texas--()--Premier Biomedical, Inc.(OTCQB:"BIEI") a biotech research company focused on discovering, developing, and commercializing medical treatments for a wide range of diseases in humans, including innovative therapies for breast cancer, as well as for fibromyalgia, neuropathy, atherosclerosis and muscular dystrophy confirmed today that its planned Brazilian joint venture partner, Auramedi Farmacêutica, Ltd., has announced its intention to invest up to BRL$25 Million (USD$ 6 Million) to establish facilities for the manufacture, distribution and sale of Premier Biomedical drugs and other treatments in Brazil and South America.

A source inside Auramedi, familiar with the matter, has confirmed the intentions of the Brazilian company to develop the JV, and the possibility of accelerating the investment, once the JV partnership is consummated. “Auramedi’s master plan established that we would invest from 20 to 25 Million Brazilian Real over the next five years, to set up our facility. However, with the advent of the joint venture, this amount could be invested earlier, due to the confidence we have regarding the success potential of this endeavor.” the source said.

Premier is working, with Auramedi's support, on investigations to apply Premier’s extracorporeal technology toward finding a cure for the Zika and Dengue viruses.

William A. Hartman, President and CEO of Premier Biomedical stated, “We are extremely pleased with the progress and interest Auramedi has shown in the development and success of this Brazilian joint venture. Their top management has participated in regular meetings with Premier, and continues to do so. We are confident the remaining issues in establishing the JV will be resolved in short order.”

Contact William Hartman at (724) 633-7033, PR@premierbiomedical.com.

About Premier Biomedical, Inc.

Premier Biomedical, Inc. (OTCQB: BIEI) is a research-based company that intends to discover and develop medical treatments for a wide range of diseases in humans. Premier has obtained, via license agreements, the technology behind three granted U.S. patents, multiple pending provisional patents, and a PCT Europe National Patent. Founded in 2010, Premier has partnered with the Department of Defense with Center of Expertise at the William Beaumont Army Medical Center. The company's R&D efforts are centered in El Paso, TX. The Company is a fully-reporting issuer whose common stock trades on the OTCQB marketplace maintained by OTC Markets Group, Inc. under the ticker symbol "BIEI".

For more information, visit our website http://www.premierbiomedical.com/

About Auramedi Farmacêutica Ltda

Auramedi (http://www.auramedi.com/) is a Brazilian pharmaceutical company, dedicated to bringing to the Brazilian health care market innovation and increment in each of its products. Auramedi is highly committed to finding solutions and treatments to achieve the best result for patients, prescribers, caregivers, consumers and all those who face challenges in their health or well-being, providing access to the best medical and pharmaceutical treatments science are able to provide.

Safe Harbor Notice

Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.

Contacts

Premier Biomedical, Inc.
William Hartman, 724-633-7033
PR@premierbiomedical.com.

Release Summary

Premier Biomedical Announces Intended $6 Million Investment by Brazilian Joint Venture Partner, Auramedi, to Manufacture, Market and Distribute Premier’s New Technology Products

Contacts

Premier Biomedical, Inc.
William Hartman, 724-633-7033
PR@premierbiomedical.com.